NCT01217749View on ClinicalTrials.gov

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

71

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

June 30, 2013

Study Completion Date

May 31, 2014

Conditions

B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaProlymphocyctic LeukemiaRichter's Transformation

Interventions

DRUG

PCI-32765

420 mg PO daily

DRUG

ofatumumab

per package insert as an IV infusion

Trial Locations (1)

43210

The Ohio State University, Columbus

Sponsors

Lead Sponsor

Pharmacyclics LLC.

All Listed Sponsors

collaborator

Ohio State University

OTHER

lead

Pharmacyclics LLC.

INDUSTRY